Tokyo, June 26 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000057863) titled 'Examination of biomarkers for progression or long-term response in trastuzumab deruxtecan (EXPLORE study)' on May 19
Study Type:
Observational
Study Design:
Primary Sponser:
Institute - Eisai Co.,Ltd.
Condition:
Condition - HER2-negative or HER2-low unresectable or recurrent breast cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Intervention:
Eligibility:
Age-lower limit - 18
years-old
1. HER2 positive/early progression; 2nd line therapy: less than 9M, 3rd line therapy: less than 6M, 4th line therapy: less than 6M
2. HER2 positive/effective; 2nd line therapy: more...